A Plasmodium vivax experimental human infection model for evaluating efficacy of interventions
Open Access
- 27 April 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 130 (6), 2920-2927
- https://doi.org/10.1172/jci134923
Abstract
BACKGROUND. Interventions that interrupt Plasmodium vivax transmission or eliminate dormant P. vivax liver-stage parasites will be essential for malaria elimination. Development of these interventions has been hindered by the lack of P. vivax in vitro culture and could be accelerated by a safe and reproducible clinical model in malaria-naive individuals. METHODS. Healthy, malaria-naive adults were enrolled in 2 studies to assess the safety, infectivity, and transmissibility of a new P. vivax isolate. Participants (Study 1, n = 2; Study 2, n = 24) were inoculated with P. vivax–infected red blood cells to initiate infection, and were treated with artemether-lumefantrine (Study 1) or chloroquine (Study 2). Primary endpoints were safety and infectivity of the new isolate. In Study 2, transmission to mosquitoes was also evaluated using mosquito feeding assays, and sporozoite viability was assessed using in vitro cultured hepatocytes. RESULTS. Parasitemia and gametocytemia developed in all participants and was cleared by antimalarial treatment. Adverse events were mostly mild or moderate and none were serious. Sixty-nine percent of participants (11/16) were infectious to Anopheles mosquitoes at peak gametocytemia. Mosquito infection rates reached 97% following membrane feeding with gametocyte-enriched blood, and sporozoites developed into liver-stage schizonts in culture. CONCLUSION. We have demonstrated the safe, reproducible, and efficient transmission of P. vivax gametocytes from humans to mosquitoes, and have established an experimental model that will accelerate the development of interventions targeting multiple stages of the P. vivax life cycle. TRIAL REGISTRATION. ACTRN12614000930684 and ACTRN12616000174482. FUNDING. (Australian) National Health and Medical Research Council Program Grant 1132975 (Study 1). Bill and Melinda Gates Foundation (OPP1111147) (Study 2).Funding Information
- (Australian) NHMRC (Program Grant: 1132975)
- Bill and Melinda Gates Foundation (OPP1111147)
This publication has 28 references indexed in Scilit:
- Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmissioneLife, 2014
- Comparison of three methods for detection of gametocytes in Melanesian children treated for uncomplicated malariaMalaria Journal, 2014
- Plasmodium vivax Sporozoite Challenge in Malaria-Naïve and Semi-Immune Colombian VolunteersPLOS ONE, 2014
- Experimentally Induced Blood-Stage Plasmodium vivax Infection in Healthy VolunteersThe Journal of Infectious Diseases, 2013
- Malariotherapy – Insanity at the Service of MalariologyAdvances In Parasitology, Vol 64, 2013
- Evidence and Implications of Mortality Associated with Acute Plasmodium vivax MalariaClinical Microbiology Reviews, 2013
- G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based MapPLoS Medicine, 2012
- Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and EliminationClinical Microbiology Reviews, 2011
- Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasiteThe Lancet Infectious Diseases, 2009
- PROCEDURES USED AT STATEVILLE PENITENTIARY FOR THE TESTING OF POTENTIAL ANTIMALARIAL AGENTS 1JCI Insight, 1948